Opportunity Assessment
Validate clinical demand for genomics in a new market. Covers oncologist and clinical geneticist interviews, regulatory pathway mapping, reimbursement landscape research, and a Go/Defer/Kill recommendation.
Learn more →
Our POV · 2026
Genomics and precision medicine market entry strategy
Genomics and precision medicine – using genetic information to personalise disease prevention, diagnosis, and treatment – is transitioning from research tool to clinical practice at accelerating speed. Genomic testing companies, pharmacogenomics businesses, cancer genomics diagnostic providers, and precision medicine technology platforms are all evaluating new market entry opportunities as sequencing costs fall, clinical evidence accumulates, and healthcare systems invest in genomic medicine capabilities. GreyRadius helps genomics businesses validate clinical demand, navigate regulatory requirements, execute GTM plans, and raise capital.
Why now? Government genomics investment is creating institutional demand – the UK Biobank, UAE's National Genome Program, Saudi Arabia's precision medicine initiative, India's genome sequencing programme, and Singapore's National Precision Medicine strategy are all creating government-funded genomics infrastructure that creates procurement opportunities for genomics technology companies. Oncology is driving the fastest clinical adoption as companion diagnostics become standard of care.
$60B+
Global genomics market by 2030
Growing at 16% annually as sequencing costs fall, clinical applications multiply, and healthcare systems invest in precision medicine infrastructure.
30+
Primary interviews per genomics mandate
Oncologists, clinical geneticists, and hospital administrators – every engagement grounded in direct primary research.
8 weeks
Market entry strategy delivery
AI-augmented regulatory pathway mapping and clinical demand research delivers genomics market entry strategies efficiently.
Market Intelligence
What the data says.
Global genomics market is projected to reach $60B by 2030 – growing at 16% annually as sequencing costs continue to fall, clinical applications multiply, and healthcare system investment in precision medicine infrastructure accelerates.
Oncology companion diagnostics is the largest near-term genomics application – next-generation sequencing for tumour profiling is becoming standard of care for multiple cancer types, driving significant clinical genomics demand.
Pharmacogenomics is growing rapidly – drug-gene interaction testing before prescribing medications is improving patient safety and outcomes, creating adoption in cardiology, psychiatry, and primary care.
Population genomics programmes are creating healthcare system infrastructure – large-scale government genome sequencing programmes are building the data infrastructure that precision medicine clinical applications require.
Market Reality
What makes this market hard.
- Clinical regulatory approval for genomic diagnostics is complex – laboratory developed tests, IVD classification, and companion diagnostic approval all have different regulatory pathways with different evidence requirements.
- Clinical utility demonstration is required for reimbursement – healthcare systems and payers require robust clinical evidence that genomic testing improves patient outcomes before approving reimbursement.
- Laboratory infrastructure requirements are significant – genomic testing requires specialised bioinformatics infrastructure, sequencing equipment, and CLIA/ISO-certified laboratory operations.
- Data privacy for genomic data is a sensitive and evolving regulatory area – genomic data is the most sensitive personal data category and faces specific regulatory protection that varies by market.
Our Work
What we solve for clients.
If you recognise your situation below, we can help.
Clinical demand validation
You need to validate which clinical specialties and hospital systems are actively adopting genomic testing and what evidence standards and regulatory requirements they have.
Regulatory and laboratory certification pathway
You need to understand IVD classification, laboratory certification, and clinical validation requirements for your genomic test in your target market.
Hospital and laboratory partner identification
You need to identify reference hospitals, clinical genomics laboratories, and pathology networks as clinical validation and distribution partners.
GTM for a genomics company
You have a genetic test, sequencing platform, or precision medicine tool and need a go-to-market strategy covering clinical and hospital buyer acquisition.
Raising capital for a genomics venture
You are raising investment and need a pitch book grounded in clinical demand data, market sizing, and regulatory pathway clarity.
Government programme partnership
You need to identify national genome programmes and government precision medicine initiatives as anchor institutional partners.
Our Services
How we engage.
Every engagement is grounded in primary research and delivers a measurable outcome.
Feasibility & TEV
Full financial and operational feasibility for genomics investments. Covers clinical adoption modelling, laboratory economics, regulatory pathway cost, and investor-ready projections.
Learn more →Market Entry Execution
End-to-end market entry for genomics companies. Regulatory pathway, reference hospital identification, clinical KOL development, and first-clinical-deployment milestone.
Learn more →GTM Execution-as-a-Service
Embedded GTM team for genomics platforms. Hospital and clinical laboratory outreach, government programme pipeline, and first-revenue milestone tracking.
Learn more →Pitchbook & Fundraising
Investor-ready pitch books for genomics ventures. Clinical-demand-validated market sizing, regulatory timeline, and investor identification.
Learn more →AI Consulting
AI use-case prioritisation in genomics – from variant interpretation and clinical decision support to population genomics analysis and personalised treatment recommendation.
Learn more →Why GreyRadius.
Primary research-led
80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Expert-led, AI-enabled delivery
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
Outcomes, not reports
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Case Studies
Mandates we've run.
Healthcare · Market Entry
Gulf market entry for a South Asian pharma company
Regulatory mappedDistributor shortlistFirst listings
View all case studies →
Healthcare · GTM Execution
GTM for a digital-health platform in Southeast Asia
Clinic partnershipsB2B pipelineFirst ARR
View all case studies →
Healthcare · Assessment
Opportunity assessment for a medical-device launch in India
Clinical interviewsRegulatory reviewRevenue model
View all case studies →
FAQ
Common questions.
Does GreyRadius work with clinical genomics diagnostic companies or also with consumer genomics and pharmacogenomics companies?+
All three. We work with clinical diagnostic companies on regulatory pathway and market entry, pharmacogenomics companies on GTM and market entry, and consumer genomics companies on market entry and fundraising.
What genomics markets does GreyRadius cover?+
Gulf, Southeast Asia, South Asia, and Europe – markets with active government genomics programmes and growing clinical precision medicine adoption.
How long does a genomics market entry engagement take?+
Typically 8–12 weeks for clinical demand research, regulatory pathway mapping, and reimbursement landscape assessment.
Can GreyRadius identify government genomics programme partnerships for genomics companies?+
Yes. Government precision medicine programme mapping and partnership identification are part of our market entry service.
Stay informed
Market intelligence for Healthcare & Life Sciences leaders.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Related market entry guides
Ready to enter this market?
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia.
Book a call